Tyler P Robin1, Bernard L Jones1, Arya Amini2, Matthew Koshy3, Laurie E Gaspar1, Arthur K Liu1, Sameer K Nath1, Brian D Kavanagh1, D Ross Camidge4, Chad G Rusthoven5. 1. Department of Radiation Oncology, University of Colorado School of Medicine, Aurora, CO, United States. 2. Department of Radiation Oncology, City of Hope Comprehensive Cancer Center, Duarte, CA, United States. 3. Department of Radiation Oncology, University of Illinois at Chicago, Chicago, IL, United States; Department of Radiation and Cellular Oncology, The University of Chicago, Chicago, IL, United States. 4. Division of Medical Oncology, Department of Medicine, University of Colorado School of Medicine, Aurora, CO, United States. 5. Department of Radiation Oncology, University of Colorado School of Medicine, Aurora, CO, United States. Electronic address: chad.rusthoven@ucdenver.edu.
Abstract
INTRODUCTION: Whole-brain radiation therapy (WBRT) is the standard approach for brain metastases (BM) arising in patients with small-cell lung cancer (SCLC), but the neurocognitive toxicities of WBRT are well documented. For this reason, stereotactic radiosurgery (SRS) alone is the preferred modality for limited BM in most histologies, but in SCLC there are few data exploring this approach. METHODS: We queried the National Cancer Database (NCDB) for patients with SCLC with BM at diagnosis and stratified by upfront SRS compared with upfront WBRT ± SRS. We utilized multivariate Cox regression and propensity score matching (PSM) to determine the impact on overall survival (OS) of each approach. RESULTS: 5952 eligible patients (WBRT: 5752; SRS: 200) were identified from 2010 to 2014 with a median follow-up of 40.0 months. Upfront SRS was associated with superior OS (median 10.8 vs 7.1 months, HR 0.65, 95% CI 0.55-0.75, p < 0.001), which persisted on multivariate analysis controlling for comorbidities, extracranial metastases, age, race/ethnicity, and gender (HR 0.70, 95% CI 0.60-0.81, p < 0.001). These results were confirmed in PSM analysis. A subset analysis comparing outcomes after SRS vs SRS + WBRT showed no differences in OS (p = .601). CONCLUSIONS: To our knowledge, this is the largest dataset of patients treated with SRS alone for SCLC. The observation of favorable OS with SRS alone in this contemporary dataset suggests that SRS alone may be appropriate for some patients with SCLC. Prospective investigations of SRS in SCLC are warranted.
INTRODUCTION: Whole-brain radiation therapy (WBRT) is the standard approach for brain metastases (BM) arising in patients with small-cell lung cancer (SCLC), but the neurocognitive toxicities of WBRT are well documented. For this reason, stereotactic radiosurgery (SRS) alone is the preferred modality for limited BM in most histologies, but in SCLC there are few data exploring this approach. METHODS: We queried the National Cancer Database (NCDB) for patients with SCLC with BM at diagnosis and stratified by upfront SRS compared with upfront WBRT ± SRS. We utilized multivariate Cox regression and propensity score matching (PSM) to determine the impact on overall survival (OS) of each approach. RESULTS: 5952 eligible patients (WBRT: 5752; SRS: 200) were identified from 2010 to 2014 with a median follow-up of 40.0 months. Upfront SRS was associated with superior OS (median 10.8 vs 7.1 months, HR 0.65, 95% CI 0.55-0.75, p < 0.001), which persisted on multivariate analysis controlling for comorbidities, extracranial metastases, age, race/ethnicity, and gender (HR 0.70, 95% CI 0.60-0.81, p < 0.001). These results were confirmed in PSM analysis. A subset analysis comparing outcomes after SRS vs SRS + WBRT showed no differences in OS (p = .601). CONCLUSIONS: To our knowledge, this is the largest dataset of patients treated with SRS alone for SCLC. The observation of favorable OS with SRS alone in this contemporary dataset suggests that SRS alone may be appropriate for some patients with SCLC. Prospective investigations of SRS in SCLC are warranted.
Authors: Mustafa S Ascha; Kaitlyn Funk; Andrew E Sloan; Carol Kruchko; Jill S Barnholtz-Sloan Journal: Clin Exp Metastasis Date: 2019-11-08 Impact factor: 5.150
Authors: Christopher P Cifarelli; John A Vargo; Wei Fang; Roman Liscak; Khumar Guseynova; Ronald E Warnick; Cheng-Chia Lee; Huai-Che Yang; Hamid Borghei-Razavi; Tonmoy Maiti; Zaid A Siddiqui; Justin C Yuan; Inga S Grills; David Mathieu; Charles J Touchette; Diogo Cordeiro; Veronica Chiang; Judith Hess; Christopher J Tien; Andrew Faramand; Hideyuki Kano; Gene H Barnett; Jason P Sheehan; L Dade Lunsford Journal: Neurosurgery Date: 2020-09-15 Impact factor: 4.654
Authors: Ayal A Aizer; Nayan Lamba; Manmeet S Ahluwalia; Kenneth Aldape; Adrienne Boire; Priscilla K Brastianos; Paul D Brown; D Ross Camidge; Veronica L Chiang; Michael A Davies; Leland S Hu; Raymond Y Huang; Timothy Kaufmann; Priya Kumthekar; Keng Lam; Eudocia Q Lee; Nancy U Lin; Minesh Mehta; Michael Parsons; David A Reardon; Jason Sheehan; Riccardo Soffietti; Hussein Tawbi; Michael Weller; Patrick Y Wen Journal: Neuro Oncol Date: 2022-10-03 Impact factor: 13.029
Authors: Joseph A Miccio; Andrew Barsky; Sarah Gao; Vivek Verma; Sonal S Noticewala; Vikram Jairam; Skyler B Johnson; James B Yu; James E Hansen; Sanjay Aneja; Yi An; Roy H Decker; S Bulent Omay; Jing Li; Goldie A Kurtz; Michelle Alonso-Basanta; John Y K Lee; Veronica L Chiang; Henry S Park Journal: J Radiosurg SBRT Date: 2020
Authors: Chad G Rusthoven; Masaaki Yamamoto; Denise Bernhardt; Derek E Smith; Dexiang Gao; Toru Serizawa; Shoji Yomo; Hitoshi Aiyama; Yoshinori Higuchi; Takashi Shuto; Atsuya Akabane; Yasunori Sato; Ajay Niranjan; Andrew M Faramand; L Dade Lunsford; James McInerney; Leonard C Tuanquin; Brad E Zacharia; Veronica Chiang; Charu Singh; James B Yu; Steve Braunstein; David Mathieu; Charles J Touchette; Cheng-Chia Lee; Huai-Che Yang; Ayal A Aizer; Daniel N Cagney; Michael D Chan; Douglas Kondziolka; Kenneth Bernstein; Joshua S Silverman; Inga S Grills; Zaid A Siddiqui; Justin C Yuan; Jason P Sheehan; Diogo Cordeiro; Kename Nosaki; Takahashi Seto; Christopher P Deibert; Vivek Verma; Samuel Day; Lia M Halasz; Ronald E Warnick; Daniel M Trifiletti; Joshua D Palmer; Albert Attia; Benjamin Li; Christopher P Cifarelli; Paul D Brown; John A Vargo; Stephanie E Combs; Kerstin A Kessel; Stefan Rieken; Samir Patel; Matthias Guckenberger; Nicolaus Andratschke; Brian D Kavanagh; Tyler P Robin Journal: JAMA Oncol Date: 2020-07-01 Impact factor: 31.777